RPM:NYSERPM International Inc. Analysis
Data as of 2026-04-29 - not real-time
$103.70
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
RPM is trading at $103.7, just below its 20‑day (≈$105.15) and 50‑day (≈$105.19) simple moving averages, with a bearish MACD crossover (MACD line $0.61 vs signal $0.82) and a neutral RSI of 46.6. High 30‑day volatility (≈44.6%), a beta near 1.0, decreasing volume, and a technical support level around $95 suggest short‑term downside pressure, while resistance sits near $113.
On the fundamentals side, RPM posted $7.71 B in revenue with 8.9% YoY growth, a solid ROE of 22.9%, and a sustainable dividend yield of 2.08% backed by a 40% payout ratio. Despite a DCF‑derived fair value of only $38, analysts maintain a strong‑buy stance with a median price target of $125, implying roughly 20% upside from current levels. The combination of strong cash generation, dividend‑king status, and positive earnings surprises supports a medium‑term buying case, even as the stock appears overvalued by traditional valuation metrics.
On the fundamentals side, RPM posted $7.71 B in revenue with 8.9% YoY growth, a solid ROE of 22.9%, and a sustainable dividend yield of 2.08% backed by a 40% payout ratio. Despite a DCF‑derived fair value of only $38, analysts maintain a strong‑buy stance with a median price target of $125, implying roughly 20% upside from current levels. The combination of strong cash generation, dividend‑king status, and positive earnings surprises supports a medium‑term buying case, even as the stock appears overvalued by traditional valuation metrics.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and price below short‑term SMAs
- Decreasing volume and high near‑term volatility
- Strong dividend yield and sustainable payout
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst consensus strong‑buy with median target $125
- Revenue growth of 8.9% and solid ROE
- Sustainable dividend and healthy cash flow
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Consistent dividend‑king track record
- Cyclical exposure in specialty chemicals sector
- Overvaluation relative to DCF fair value
Key Metrics & Analysis
Financial Health
Revenue Growth8.90%
Profit Margin8.63%
P/E Ratio20.0
ROE22.90%
ROA8.13%
Debt/Equity92.06
P/B Ratio4.2
Op. Cash Flow$805.8M
Free Cash Flow$381.0M
Technical Analysis
TrendBearish
RSI46.8
Support$94.99
Resistance$113.17
MA 20$105.15
MA 50$105.19
MA 200$111.49
MACDBearish
VolumeDecreasing
Fear & Greed Index89.59
Valuation
Fair Value$37.97
Target Price$128.07
Upside/Downside23.50%
GradeOvervalued
TypeBlend
Dividend Yield2.08%
Risk Assessment
Beta1.01
Volatility44.61%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.